characteristics, treatment regimens, and survival outcomes between non-metastatic IBC patients and comprehensively matched patients with stage III invasive non-IBC based on age, stage, and biomarker status. Results : A total of 165 patients (84 IBC, 81 non
Search Results
HSR22-143: Outcome Differences Amongst Stage-Matched Inflammatory vs Non-Inflammatory Breast Cancer Patients
Michael Grimm, Kai Johnson, Patrick Schnell, Ashley Pariser, Margaret Gatti-Mays, Jeffrey VanDeusen, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Preeti Sudheendra, Bhuvaneswari Ramaswamy, Ko Un Park, Sachin R Jhawar, Amy Kerger, and Mathew A Cherian
BPI20-009: Impact of Preoperative Biliary Drainage on Postoperative Outcome for Obstructive Jaundice Patients
Zhihui Gao, Shen Sheng, Liu Han, Ni Xiaoling, Suo Tao, Wang Yueqi, and Houbao Liu
Background and aim: Indications of preoperative biliary drainage (PBD) for malignant obstructive jaundice are still controversial. The present study aims to assess the impact of preoperative biliary drainage on postoperative outcome, to define the
Leveraging Surgical Case Volume in Improving Cancer Care Outcomes: Where Do We Go From Here?
Henry Soo-Min Park
Over the course of the past quarter century, an increasing number of observational studies have been published investigating how surgeon and hospital experience can influence the outcomes of patients undergoing complex surgeries. Early studies
CLO23-046: Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy
Stereotactic Ablative Radiotherapy for Non–Small Cell Lung Cancer: Rationale and Outcomes
Puneeth Iyengar and Robert D. Timmerman
To understand why radiation oncologists moved toward the use of SABR in treating primary NSCLCs and metastatic disease to the lungs, the poor outcomes in controlling these disease states with fractionated radiation therapy (eg, 25–37 daily treatments
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong
in survival over the past decade. 2 Advances in personalized therapies for advanced NSCLC (aNSCLC), which allow treatment based on the genetic makeup of a tumor, have significantly contributed to the improved outcomes of patients. 2 Despite the
EPR22-121: Racial Disparities in Survival Outcomes Among Patients With Appendiceal Cancer
Krista Michelle Wong, Seshma Ramsawak, and Hasan Abuamsha
racial disparity in appendiceal cancer-specific survival exists among appendiceal cancer SEER patients. Further research is needed to address the underlying cause of these disparities in order to improve outcomes. Table: Bivariable and multivariable
CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer
Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas
chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration
HSR22-134: Outcomes of Patients who Received Radiation Therapy for Brain Metastases From Gynecologic Malignancies
Eric Chen, Todd Aquino-Michaels, Sadhvi Batra, Riley Lochner, Anthony Rizzo, Ravi Kyasaram, Eleanor Harris, Tiffany Hodges, Lindsay Ferguson, and Serah Choi
Background : Even among patients with stage IV gynecologic cancers, metastases to the brain are rare and prognosis remains poor. Given the paucity of data, this study aimed to describe the outcomes of this patient population who underwent
Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?
Alejandro Garcia-Horton and Jeffrey H. Lipton
possible without widespread treatment and availability of TKIs, resulting in disease control and molecular response. Treatment-free remission (TFR) has emerged as a new goal for many patients with CML as a distinct outcome other than overall survival (OS
